Thyroid hormone receptor progresses to phase 2b for NASH

Viking Therapeutics announced the initiation of a phase 2b trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist undergoing investigation for patients with nonalcoholic steatohepatitis, according to a press release.“We are excited to advance VK2809 into the next stage of development and look forward to assessing its safety and efficacy in this important trial,” Brian Lian, PhD, CEO of Viking, said in the release. “Given the high unmet need for new therapies to treat NASH, and VK2809’s promising initial data on both liver fat and plasma lipids,Read More

Share on facebook
Share on twitter
Share on linkedin